BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 15244186)

  • 1. Serum paraoxonase levels in pancreatic cancer.
    Akçay MN; Polat MF; Yilmaz I; Akçay G
    Hepatogastroenterology; 2003 Dec; 50 Suppl 2():ccxxv-ccxxvii. PubMed ID: 15244186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum paraoxonase levels in gastric cancer.
    Akçay MN; Yilmaz I; Polat MF; Akçay G
    Hepatogastroenterology; 2003 Dec; 50 Suppl 2():cclxxiii-cclxxv. PubMed ID: 15244199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum paraoxonase/arylesterase activities in phenylketonuric patients on diet.
    Schulpis KH; Bartzeliotou A; Tsakiris S; Gounaris A; Papassotiriou I
    Eur J Clin Nutr; 2007 Jun; 61(6):803-8. PubMed ID: 17203019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome.
    Delgado Alves J; Ames PR; Donohue S; Stanyer L; Nourooz-Zadeh J; Ravirajan C; Isenberg DA
    Arthritis Rheum; 2002 Oct; 46(10):2686-94. PubMed ID: 12384928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of serum paraoxonase activity with insulin sensitivity and oxidative stress in hyperthyroid and TSH-suppressed nodular goitre patients.
    Yavuz DG; Yüksel M; Deyneli O; Ozen Y; Aydin H; Akalin S
    Clin Endocrinol (Oxf); 2004 Oct; 61(4):515-21. PubMed ID: 15473886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes of serum paraoxonase (an HDL-cholesterol-associated lipophilic antioxidant) and arylesterase activities in severe preeclamptic women.
    Kumru S; Aydin S; Gursu MF; Ozcan Z
    Eur J Obstet Gynecol Reprod Biol; 2004 Jun; 114(2):177-81. PubMed ID: 15140512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inverse correlation of serum paraoxonase and homocysteine thiolactonase activities and antioxidant capacity of high-density lipoprotein with the severity of cardiovascular disease in persons with type 2 diabetes mellitus.
    Lakshman MR; Gottipati CS; Narasimhan SJ; Munoz J; Marmillot P; Nylen ES
    Metabolism; 2006 Sep; 55(9):1201-6. PubMed ID: 16919539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of alterations in plasma lipid profile levels in breast cancer.
    Franky Dhaval Shah ; Shilin Nandubhai Shukla ; Pankaj Manubhai Shah ; Patel HR; Prabhudas Shankerbhai Patel
    Integr Cancer Ther; 2008 Mar; 7(1):33-41. PubMed ID: 18292593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase.
    Aviram M; Rosenblat M; Bisgaier CL; Newton RS; Primo-Parmo SL; La Du BN
    J Clin Invest; 1998 Apr; 101(8):1581-90. PubMed ID: 9541487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum paraoxonase-1 activity in women with endometriosis and its relationship with the stage of the disease.
    Verit FF; Erel O; Celik N
    Hum Reprod; 2008 Jan; 23(1):100-4. PubMed ID: 18000171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum paraoxonase activity in uremic predialysis and hemodialysis patients.
    Dirican M; Akca R; Sarandol E; Dilek K
    J Nephrol; 2004; 17(6):813-8. PubMed ID: 15593056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population.
    Elkiran ET; Mar N; Aygen B; Gursu F; Karaoglu A; Koca S
    BMC Cancer; 2007 Mar; 7():48. PubMed ID: 17362500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paraoxonase-1 (PON-1) genotype and activity and in vivo oxidized plasma low-density lipoprotein in Type II diabetes.
    Sampson MJ; Braschi S; Willis G; Astley SB
    Clin Sci (Lond); 2005 Aug; 109(2):189-97. PubMed ID: 15853770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Relation between paraoxonase activity, other HDL components and inflammatory state in hemodialyzed patients].
    González AI; Brites F; Elbert A; Gómez-Rosso L; Berg G; Wikinski R; Schreier L
    Medicina (B Aires); 2010; 70(6):508-12. PubMed ID: 21163737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol.
    Bergheanu SC; Van Tol A; Dallinga-Thie GM; Liem A; Dunselman PH; Van der Bom JG; Jukema JW
    Curr Med Res Opin; 2007 Sep; 23(9):2235-40. PubMed ID: 17692153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High plasma C-reactive protein (CRP) is related to low paraoxonase-I (PON-I) activity independently of high leptin and low adiponectin in type 2 diabetes mellitus.
    Dullaart RP; de Vries R; Sluiter WJ; Voorbij HA
    Clin Endocrinol (Oxf); 2009 Feb; 70(2):221-6. PubMed ID: 18505467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia.
    Paragh G; Törocsik D; Seres I; Harangi M; Illyés L; Balogh Z; Kovács P
    Curr Med Res Opin; 2004 Aug; 20(8):1321-7. PubMed ID: 15324535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HDL oxidability and its protective effect against LDL oxidation in Type 2 diabetic patients.
    Sanguinetti SM; Brites FD; Fasulo V; Verona J; Elbert A; Wikinski RL; Schreier LE
    Diabetes Nutr Metab; 2001 Feb; 14(1):27-36. PubMed ID: 11345163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearance.
    Gugliucci A; Mehlhaff K; Kinugasa E; Ogata H; Hermo R; Schulze J; Kimura S
    Clin Chim Acta; 2007 Feb; 377(1-2):213-20. PubMed ID: 17118352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.